Repligen Corporation - Common Stock (RGEN)

What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 7.3% in the morning session after the company reported fir...

Repligen (RGEN) Q1 2026 Earnings Call Transcript

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 14.8% ...

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results this Tuesday before the bell. Here’s what investors sh...

What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 5.3% in the afternoon session after an SEC filing revealed t...

What Happened? A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and ener...

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...

Repligen trades at $124.97 and has moved in lockstep with the market. Its shares have returned 7.6% over the last six months while the S&P 500 has gained 6.6...

A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. 

Repligen (RGEN) Q4 2025 Earnings Call Transcript

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 18.1% year on year to $197.9 million. The company expects the full year’s revenue to be around $825 million, close to analysts’ estimates. Its non-GAAP profit of $0.49 per share was 10.4% above analysts’ consensus estimates.

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday before market hours. Here’s what to expect.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.